Piper Sandler raised the firm’s price target on ImmunityBio (IBRX) to $7 from $5 and keeps an Overweight rating on the shares. The firm notes U.S. ANKTIVA Net revenues grew about 700% to $113M in 2025, and it now projects $180M in 2026. Based on strong interim data, Piper is confident positive QUILT-2.005 data in Q4 2026 could lead to ANKTIVA label expansion in 2027.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX: